Abstract
Antimicrobial resistance among Enterobacteriaceae has been increasing globally especially due to extended-spectrum-β-lactamases (ESBLs), which typically necessitate the use of carbapenems for treatment of serious infections. Emerging carbapenem-resistant Enterobacteriaceae further complicate therapy. As part of the Study for Monitoring Antimicrobial Resistance Trends (SMART), this analysis examined the recent activity of a key carbapenem (ertapenem) and other important therapeutic options against Enterobacteriaceae. From 2012 to 2016, 224 hospitals in 57 countries collected up to 100 consecutive gram-negative bacilli from intra-abdominal (IAI) and 50 from urinary tract infections (UTI) per year, totaling 106,300 Enterobacteriaceae isolates. Susceptibility was determined using CLSI broth microdilution and breakpoints. Although statistically significant decreasing trends in ertapenem activity against Enterobacteriaceae were found in all regions except Middle East, the actual size of the decreases was < 3 percentage points, and susceptibility in 2015-2016 remained ca. 90% or higher, ranging from 89.5% in Asia to 97.3% in US/Canada. Of the comparators, only amikacin exceeded these results. Ertapenem was active against > 90% of isol...Continue Reading
References
Mar 11, 2005·Expert Review of Anti-infective Therapy·George G ZhanelDaryl J Hoban
May 27, 2005·The Journal of Antimicrobial Chemotherapy·Johann D D PitoutLaurent Poirel
Dec 12, 2007·Antimicrobial Agents and Chemotherapy·Christian G GiskeUNKNOWN ReAct-Action on Antibiotic Resistance
Dec 19, 2007·Antimicrobial Agents and Chemotherapy·Mitchell J SchwaberYehuda Carmeli
Apr 28, 2010·Antimicrobial Agents and Chemotherapy·Stephen P HawserFernando Baquero
Jun 19, 2012·The Korean Journal of Internal Medicine·David M Livermore
Sep 1, 2012·Current Pharmaceutical Design·Johann D D Pitout
Nov 30, 2013·Pharmaceuticals·Ian MorrisseyDouglas Biedenbach
May 16, 2014·The Journal of Antimicrobial Chemotherapy·George G ZhanelDaryl J Hoban
Jun 17, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P Nordmann, L Poirel
Mar 25, 2015·Antimicrobial Agents and Chemotherapy·Sibylle H LobDaniel F Sahm
May 1, 2015·Clinical Microbiology Reviews·Amy J MathersJohann D D Pitout
May 21, 2015·BMC Microbiology·Maria Teresa MontagnaGiuseppina Caggiano
Feb 26, 2016·The Journal of Antimicrobial Chemotherapy·Belén Gutiérrez-GutiérrezUNKNOWN REIPI/ESGBIS/INCREMENT Group
Mar 2, 2016·Antimicrobial Agents and Chemotherapy·James A KarlowskyDaniel F Sahm
Jun 17, 2016·Diagnostic Microbiology and Infectious Disease·Sibylle H LobDaniel F Sahm
Jun 1, 2013·Journal of Global Antimicrobial Resistance·Ursula Theuretzbacher
Jan 5, 2017·Journal of Medical Microbiology·James A KarlowskyDaniel F Sahm
Jan 27, 2017·MSphere·Anna GiammancoMichael J Dowzicky
Mar 3, 2017·BMC Infectious Diseases·Pinyo RattanaumpawanVisanu Thamlikitkul
Apr 5, 2017·The Journal of Infectious Diseases·Latania K Logan, Robert A Weinstein
Apr 12, 2017·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·James A KarlowskyDaniel F Sahm
May 26, 2017·The Journal of Antimicrobial Chemotherapy·Edward R BevanPeter M Hawkey
Jun 9, 2017·BMC Infectious Diseases·Yu Bin SeoWonkeun Song
Nov 15, 2017·Future Science OA·Fidelis EnyinnayaDavid R Woodard
Citations
Nov 6, 2018·The Journal of Antimicrobial Chemotherapy·David M LivermoreNeil Woodford
Jan 31, 2019·Surgical Infections·Jennifer Rickard
Oct 15, 2019·Postgraduate Medicine·Mazen S BaderAnnie A Brooks
Dec 5, 2019·Expert Review of Anti-infective Therapy·Nicola PetrosilloFabrizio Taglietti
Mar 28, 2020·Expert Review of Anti-infective Therapy·Zvi ShimoniPaul Froom
Feb 25, 2021·Surgical Infections·Shao-Huan LanChih-Cheng Lai
Dec 14, 2021·Journal of Global Antimicrobial Resistance·Sibylle H LobDaniel F Sahm